Today: 29 October 2025
Subscribe
Browse Category

Company Analysis News 30 September 2025 - 9 October 2025

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 biospace.com; ~16 patients treated in launch year nasdaq.com. Sold to US WorldMeds (2025) adaptimmune.com Letetresgene (lete-cel, NY-ESO-1)
8 October 2025
 ·  ·  ·  ·  · 
ACM Research (ACMR) at October 1 2025: Surging Backlog, Index Inclusion and a Market Shake‑up—What’s Next for the Semiconductor Equipment Innovator?

ACM Research (ACMR) at October 1 2025: Surging Backlog, Index Inclusion and a Market Shake‑up—What’s Next for the Semiconductor Equipment Innovator?

October 1 2025 snapshot, updated: 3:00 PM EDT Latest News and Developments Surge in Backlog & Strong Demand On Sept 29 2025 ACM Research (Shanghai) announced that its backlog reached RMB 9.07 billion (US$1.27 billion), representing a 34.1 % increase
1 October 2025
 ·  ·  ·  ·  · 
Undervalued Oil Explorer Ready to Erupt? Why Pharos Energy’s New Egyptian Deal and Rising Production Could Trigger a Massive Share‑Price Surge! /updated: 3:00 PM EDT/

Undervalued Oil Explorer Ready to Erupt? Why Pharos Energy’s New Egyptian Deal and Rising Production Could Trigger a Massive Share‑Price Surge! /updated: 3:00 PM EDT/

🔍 Quick Facts about Pharos Energy (formerly SoCo International) 🏢 Company Overview and Recent Performance History & Business Model Pharos Energy plc (formerly SoCo International) is a London‑listed upstream oil and gas
1 October 2025
 ·  ·  ·  · 
1 … 3 4 5 6
Go toTop